Agenus, a US-based biotechnology company headquartered in Lexington, specializes in immuno-oncology therapies targeting cancer and infectious diseases, employing 389 staff. Its pipeline includes advanced antibodies and various immunotherapy classes.
Agenus (AGEN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Agenus's actual EPS was -$1.03, beating the estimate of -$1.69 per share, resulting in a 38.98% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
